BA attenuated the decrease in the expression of ZO-1 and Occludin induced by LPS in Caco2 cells. by Luqiong Liu (11537092)

ECoG timescales decrease during spatial attention. by Isabel Raposo (21615517)

“…Bottom: timescales significantly decrease during covert attention relative to the attend-out condition (two locations: <i>p</i> = 0.0244; four locations: <i>p</i> < 0.0001; mean ± SEM; whiskers indicate maximum and minimum; dots correspond to individual electrodes). …”

Y-27632 synergized with BA to alleviate the decrease in the expression of and abnormal localization of ZO-1 and Occludin in LPS-induced Caco2 cells. by Luqiong Liu (11537092)

NSC population and proliferation decrease drastically during the second postnatal week of DG development. by Cristina Medina-Menéndez (21800157)

Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers. by Luqiong Liu (11537092)

“…The values are expressed as the means ± SDs and were analyzed according to the variance of the factorial design. **, *** and ****denote <i>p</i> < 0.01, < 0.001 and < 0.0001, respectively; ns  =  not significant.…”

<b>Supporting data for manuscript</b> "<b>Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins</b>" by Kira Shaw (18796168)

“…<p dir="ltr">The CSV file 'Eyreetal_DrainingVein_SourceData' contains the averaged time series traces and extracted metrics from individual experiments used across Figures 1-5 in the manuscript "Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins". …”

The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness. by Gui Araujo (22170819)

“…Parameter values: interaction strengths were drawn from a half-normal distribution of zero mean and a standard deviation of 0.2, and strength for consumers was made no larger than the strength for resources. …”

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Association of each health behavior and the reported decrease in psychological well-being during the pandemic between individuals who often/very often compared to rarely/never engaged in health behaviors.... by Elie Mulhem (22537863)

“…<p>Association of each health behavior and the reported decrease in psychological well-being during the pandemic between individuals who often/very often compared to rarely/never engaged in health behaviors. …”

Effect of each health behavior on the reported decrease in physical health during the pandemic between individuals who often/very often compared to rarely/never engaged in health behaviors.... by Elie Mulhem (22537863)

“…<p>Effect of each health behavior on the reported decrease in physical health during the pandemic between individuals who often/very often compared to rarely/never engaged in health behaviors. …”

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects: